BRPI0821431A2 - Derivados de oxindol substituídos e o seu uso para o tratamento de doenças dependentes de vasopressina. - Google Patents

Derivados de oxindol substituídos e o seu uso para o tratamento de doenças dependentes de vasopressina.

Info

Publication number: BRPI0821431A2
Authority: BR; Brazil
Prior art keywords: vasopressin; treatment; dependent diseases; oxindole derivatives; substituted oxindole
Prior art date: 2007-12-27

Application number

BRPI0821431-0A

Other languages

English (en)

Inventor

Wilfried Braje

Astrid Netz

Thorsten Oost

Wolfgang Wernet

Liliane Unger

Wilfried Hornberger

Wilfried Lubisch

Original Assignee

Abbott Gmbh & Co Kg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-12-27

Filing date

2008-12-23

Publication date

2015-06-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40527553&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0821431(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-12-23 Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg

2015-06-16 Publication of BRPI0821431A2 publication Critical patent/BRPI0821431A2/pt

2015-09-22 Publication of BRPI0821431A8 publication Critical patent/BRPI0821431A8/pt

Links

GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 title 1
102000002852 Vasopressins Human genes 0.000 title 1
108010004977 Vasopressins Proteins 0.000 title 1
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 title 1
230000001419 dependent effect Effects 0.000 title 1
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
125000004095 oxindolyl group Chemical class N1(C(CC2=CC=CC=C12)=O)* 0.000 title 1
229960003726 vasopressin Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Anesthesiology (AREA)
Pulmonology (AREA)
Addiction (AREA)
Emergency Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Vascular Medicine (AREA)
Otolaryngology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Indole Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI0821431A 2007-12-27 2008-12-23 derivados de oxindol substituídos e o seu uso para o tratamento de doenças dependentes de vasopressina. BRPI0821431A8 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US927607P	2007-12-27	2007-12-27
PCT/EP2008/068254 WO2009083559A1 (de)	2007-12-27	2008-12-23	Substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen

Publications (2)

Publication Number	Publication Date
BRPI0821431A2 true BRPI0821431A2 (pt)	2015-06-16
BRPI0821431A8 BRPI0821431A8 (pt)	2015-09-22

Family

ID=40527553

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0821431A BRPI0821431A8 (pt)	2007-12-27	2008-12-23	derivados de oxindol substituídos e o seu uso para o tratamento de doenças dependentes de vasopressina.

Country Status (21)

Country	Link
US (2)	US8629148B2 (pt)
EP (1)	EP2227463B1 (pt)
JP (1)	JP5465677B2 (pt)
KR (1)	KR101570996B1 (pt)
CN (2)	CN101959878B (pt)
AU (1)	AU2008342569B2 (pt)
BR (1)	BRPI0821431A8 (pt)
CA (1)	CA2710946C (pt)
CO (1)	CO6290665A2 (pt)
CR (1)	CR11584A (pt)
DO (1)	DOP2010000197A (pt)
EC (1)	ECSP10010379A (pt)
IL (1)	IL206657A (pt)
MX (1)	MX2010007151A (pt)
MY (1)	MY157425A (pt)
NZ (1)	NZ587015A (pt)
RU (1)	RU2487872C2 (pt)
SG (1)	SG188781A1 (pt)
UA (1)	UA106200C2 (pt)
WO (1)	WO2009083559A1 (pt)
ZA (1)	ZA201005282B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0821431A8 (pt) *	2007-12-27	2015-09-22	Abbott Gmbh & Co Kg	derivados de oxindol substituídos e o seu uso para o tratamento de doenças dependentes de vasopressina.
CN103380127B (zh)	2010-12-21	2016-08-10	拜耳知识产权有限责任公司	制备n-磺酰基取代的羟吲哚的方法
CN105339366A (zh)	2013-03-14	2016-02-17	艾伯维德国有限责任两合公司	带有取代的氧杂环丁烷的2-吲哚酮衍生物及其治疗血管加压素相关疾病的用途
US9273036B2 (en)	2013-03-14	2016-03-01	AbbVie Deutschland GmbH & Co. KG	Oxindole derivatives carrying an oxetane substituent and use thereof for treating vasopressine-related diseases
US9862704B2 (en)	2013-12-20	2018-01-09	AbbVie Deutschland GmbH & Co. KG	Oxindole derivatives carrying an amine-substituted piperidyl-acetidinyl substituent and use thereof for treating vasopressine-related diseases
WO2015091931A1 (en)	2013-12-20	2015-06-25	AbbVie Deutschland GmbH & Co. KG	Oxindole derivatives carrying a piperidyl-substituted azetidinyl substituent and use thereof for treating vasopressine-related diseases
US9527856B2 (en)	2014-05-15	2016-12-27	AbbVie Deutschland GmbH & Co. KG	Oxindole compounds carrying a CO-bound spiro substituent and use thereof for treating vasopressin-related diseases

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2686878B1 (fr)	1992-01-30	1995-06-30	Sanofi Elf	Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant.
JP2949702B2 (ja) *	1993-11-26	1999-09-20	田辺製薬株式会社	２−オキソインドリン誘導体及びその製法
FR2714378B1 (fr) *	1993-12-24	1996-03-15	Sanofi Sa	Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.
FR2757157B1 (fr)	1996-12-13	1999-12-31	Sanofi Sa	Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2804115B1 (fr)	2000-01-25	2002-03-08	Sanofi Synthelabo	Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2804114B1 (fr)	2000-01-25	2002-03-08	Sanofi Synthelabo	Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2805536B1 (fr)	2000-02-25	2002-08-23	Sanofi Synthelabo	Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2810320B1 (fr)	2000-06-19	2002-08-23	Sanofi Synthelabo	Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2827604B1 (fr)	2001-07-17	2003-09-19	Sanofi Synthelabo	Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
EP1314733A1 (en) *	2001-11-22	2003-05-28	Aventis Pharma Deutschland GmbH	Indole-2-carboxamides as factor Xa inhibitors
US20050070718A1 (en)	2003-09-30	2005-03-31	Abbott Gmbh & Co. Kg	Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
DE102004033834A1 (de)	2004-07-13	2006-02-02	Abbott Gmbh & Co. Kg	Substituierte Oxindol-Derivate und diese enthaltende Arzneimittel
EP1831197A2 (de)	2004-12-31	2007-09-12	Abbott GmbH & Co. KG	Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
US8030499B2 (en) *	2005-01-28	2011-10-04	Taisho Pharmaceutical Co., Ltd.	1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle
DE102005014904A1 (de) *	2005-03-26	2007-02-01	Abbott Gmbh & Co. Kg	Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
JP2009517444A (ja) *	2005-12-02	2009-04-30	アボットゲーエムベーハーウントカンパニーカーゲー	置換オキシインドール誘導体、それを含む医薬およびそれの使用
DE102006040915A1 (de)	2006-08-26	2008-03-20	Abbott Gmbh & Co. Kg	Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
UY30846A1 (es)	2006-12-30	2008-07-31	Abbott Gmbh & Amp	Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
ES2398676T3 (es)	2007-12-07	2013-03-20	Abbott Gmbh & Co. Kg	Derivados de oxindol sustituidos con amidometilo y su uso para la producción de un medicamento para el tratamiento de enfermedades dependientes de la vasopresina
BRPI0821431A8 (pt) *	2007-12-27	2015-09-22	Abbott Gmbh & Co Kg	derivados de oxindol substituídos e o seu uso para o tratamento de doenças dependentes de vasopressina.

2008
- 2008-12-23 BR BRPI0821431A patent/BRPI0821431A8/pt active Search and Examination
- 2008-12-23 CA CA2710946A patent/CA2710946C/en not_active Expired - Fee Related
- 2008-12-23 EP EP08867378.5A patent/EP2227463B1/de not_active Not-in-force
- 2008-12-23 MY MYPI2010003063A patent/MY157425A/en unknown
- 2008-12-23 WO PCT/EP2008/068254 patent/WO2009083559A1/de not_active Ceased
- 2008-12-23 SG SG2012096160A patent/SG188781A1/en unknown
- 2008-12-23 MX MX2010007151A patent/MX2010007151A/es active IP Right Grant
- 2008-12-23 CN CN200880127614.9A patent/CN101959878B/zh not_active Expired - Fee Related
- 2008-12-23 NZ NZ587015A patent/NZ587015A/en not_active IP Right Cessation
- 2008-12-23 KR KR1020107016755A patent/KR101570996B1/ko not_active Expired - Fee Related
- 2008-12-23 CN CN201610421047.4A patent/CN106146469A/zh active Pending
- 2008-12-23 US US12/810,561 patent/US8629148B2/en not_active Expired - Fee Related
- 2008-12-23 AU AU2008342569A patent/AU2008342569B2/en not_active Ceased
- 2008-12-23 JP JP2010540123A patent/JP5465677B2/ja not_active Expired - Fee Related
- 2008-12-23 RU RU2010131173/04A patent/RU2487872C2/ru not_active IP Right Cessation
- 2008-12-23 UA UAA201009395A patent/UA106200C2/uk unknown
2010
- 2010-06-27 IL IL206657A patent/IL206657A/en not_active IP Right Cessation
- 2010-06-28 DO DO2010000197A patent/DOP2010000197A/es unknown
- 2010-07-13 CO CO10085126A patent/CO6290665A2/es not_active Application Discontinuation
- 2010-07-22 CR CR11584A patent/CR11584A/es unknown
- 2010-07-23 ZA ZA2010/05282A patent/ZA201005282B/en unknown
- 2010-07-27 EC EC2010010379A patent/ECSP10010379A/es unknown
2013
- 2013-12-03 US US14/095,162 patent/US9238642B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ECSP10010379A (es)	2010-08-31
IL206657A (en)	2015-07-30
RU2010131173A (ru)	2012-02-10
EP2227463A1 (de)	2010-09-15
UA106200C2 (uk)	2014-08-11
AU2008342569B2 (en)	2014-01-16
KR20100113095A (ko)	2010-10-20
IL206657A0 (en)	2010-12-30
MX2010007151A (es)	2010-12-06
KR101570996B1 (ko)	2015-11-23
US9238642B2 (en)	2016-01-19
CN106146469A (zh)	2016-11-23
RU2487872C2 (ru)	2013-07-20
US20110105454A1 (en)	2011-05-05
DOP2010000197A (es)	2010-08-15
SG188781A1 (en)	2013-04-30
US20140303138A1 (en)	2014-10-09
CN101959878A (zh)	2011-01-26
CR11584A (es)	2011-03-02
CA2710946C (en)	2016-05-31
AU2008342569A1 (en)	2009-07-09
MY157425A (en)	2016-06-15
US8629148B2 (en)	2014-01-14
NZ587015A (en)	2012-06-29
CN101959878B (zh)	2016-08-03
BRPI0821431A8 (pt)	2015-09-22
WO2009083559A1 (de)	2009-07-09
EP2227463B1 (de)	2016-08-17
CA2710946A1 (en)	2009-07-09
JP5465677B2 (ja)	2014-04-09
CO6290665A2 (es)	2011-06-20
ZA201005282B (en)	2015-03-25
JP2011507931A (ja)	2011-03-10

Legal Events

Date	Code	Title
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2017-10-31	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2018-02-20	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
2018-05-08	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Publication	Publication Date	Title
BRPI0810524A2 (pt)	2014-10-21	Derivado de (aza)indol e uso do mesmo para propósitos médicos
BRPI0814267A2 (pt)	2015-03-31	Agentes citotóxicos compreendendo novos derivados de tomaicmicina e o seu uso terapêutico.
BRPI0816116A2 (pt)	2015-03-03	Derivados de indol 2,3-substituídos para o tratamento de infecções virais.
BRPI0810679A2 (pt)	2014-10-07	Derivados de 4-aza indol e seu uso como fungicidas
CR10583A (es)	2009-06-05	Derivados de 1-(-d glucopiranosil)-3-(4-ciclopropilfenilmetil)-4-halogeno indol y uso de los mismos como inhibidores de los transportadores de glucosa dependientes de sodio
HUE039731T2 (hu)	2019-01-28	l,3-difenilprop-2-én-l-on-származékok alkalmazása májbetegségek kezelésére
BRPI0815154A2 (pt)	2015-03-31	Compostos de indol, composição para a prevenção ou tratamento de necrose e doenças associadas com a necrose, e, método de preparação da mesma
BRPI0810523A2 (pt)	2014-10-21	Derivado heterocíclico de 5 membros e uso do mesmo para propósitos médicos.
BRPI0716844A2 (pt)	2013-10-22	Inidores de quinase úteis para o tratamento de doenças proliferativas
CY1120741T1 (el)	2019-12-11	Θεραπεια οζωδους σκληρυνσης
ES2352576T8 (es)	2011-11-22	Inhibidores de la replicación del virus de la inmunodeficiencia humana.
DK2049525T3 (da)	2010-05-03	N-laminoheteroaryl)-1H-indol-2-carboxamid-derivater, og fremstilling og terapeutisk anvendelse deraf
CL2008002539A1 (es)	2009-07-17	Compuestos derivados de indol sustituidos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral
EA200901597A1 (ru)	2010-06-30	Гербицидно активные бициклические 1,3-дионы
BRPI0814571A2 (pt)	2015-01-06	Compostos moduladores de fxr, seu uso e composição compreendendo os mesmos
BRPI0814529A2 (pt)	2015-01-27	Derivados de 2-3-dihidrobenzo[1,4]dioxin-2-ilmetil como antagonistas alfa2c para o uso no tratamento de doenças do sistema nervoso periférico e central.
BRPI0911577A8 (pt)	2018-03-06	derivados espiro-indol para o tratamento de doenças parasíticas.
CL2007002207A1 (es)	2008-02-01	Compuestos derivados de sulfonilaminas; composicion farmaceutica; y uso de los compuestos en el tratamiento del glaucoma.
BRPI0816712A2 (pt)	2016-11-08	terapia de intervalo para o tratamento de tinnitus
IL209336B (en)	2018-07-31	Compositions for treating hyperproliferative diseases and uses thereof
BRPI0818690A2 (pt)	2015-04-14	Derivados de quinazolinediona, sua preparação e seus usos terapêuticos.
BRPI0919231A2 (pt)	2018-01-09	agonista de receptor de neuropeptídeo-2, composição farmacêutica que o compreende, seu uso e método para o tratamento ou profilaxia de enfermidades
BRPI0821431A8 (pt)	2015-09-22	derivados de oxindol substituídos e o seu uso para o tratamento de doenças dependentes de vasopressina.
BRPI0808846A2 (pt)	2019-09-24	fenoxifenilamidinas 3-substituídas e seu uso como fungicidas
PT2056804E (pt)	2014-07-11	Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de doenças oculares